Phase 2 Study of Cabazitaxel in Refractory Metastatic Gastric and Gastroesophageal Adenocarcinoma
Diseases and Conditions Researched
Esophagus; Other Digestive Organ
What is the purpose of this trial?
To demonstrate the antitumor activity as assessed by the rate of progression free survival at three
months of the sanofi-aventis product cabazitaxel 25mg/m2 IV over 1 hour every 3 weeks in subjects
with previously treated metastatic gastroesophageal adenocarcinoma who are either taxane naïve, or
taxane previously treated
Click here for detailed participation information for this trial.
|Sponsor:||Weill Medical College of Cornell University|
How will my information be used?
When you express interest in a specific study, the information from your profile will be sent to the doctor conducting that study. If you're eligible to participate, you may be contacted by a nurse or study coordinator.
If you select a health category rather than a specific study, doctors who have active studies in that area may contact you to ask if you would like to participate.
In both cases, you will be contacted by the preferred method (email or phone) that you specified in your profile.